England could lose 16,000 GPs
England could lose 16,000 GPs.
England could lose 16,000 GPs Read More »
News & Events
FDA Approves Conversion of Soliris® (eculizumab) Accelerated Approval in aHUS to Regular Approval for the Treatment of Patients with aHUS
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Pellentesque auctor aliquam lectus eget venenatis. Nam fermentum est quam, sit amet porttitor quam blandit nec. Morbi condimentum felis felis, in auctor sapien commodo ac. Donec eget felis arcu. Maecenas sit amet sapien vel eros commodo dictum. Aenean arcu orci, placerat ac consequat eget, facilisis et arcu.
European Medicines Agency Accepts Marketing Authorization Application for Asfotase Alfa as a Treatment for Patients with Hypophosphatasia
European Medicines Agency Accepts Marketing Authorization Application for Asfotase Alfa as a Treatment for Patients with HypophosphatasiaEuropean Medicines Agency Accepts Marketing Authorization Application for Asfotase Alfa as a Treatment for Patients with HypophosphatasiaEuropean Medicines Agency Accepts Marketing Authorization Application for Asfotase Alfa as a Treatment for Patients with HypophosphatasiaEuropean Medicines Agency Accepts Marketing Authorization Application
European Commission Grants Orphan Drug Designation to Soliris® (eculizumab) for the Treatment of Patients with Myasthenia Gravis (MG)
European Commission Grants Orphan Drug Designation to Soliris® (eculizumab) for the Treatment of Patients with Myasthenia Gravis (MG)European Commission Grants Orphan Drug Designation to Soliris® (eculizumab) for the Treatment of Patients with Myasthenia Gravis (MG)European Commission Grants Orphan Drug Designation to Soliris® (eculizumab) for the Treatment of Patients with Myasthenia Gravis (MG)European Commission Grants Orphan